RXRX Share Price Performance
US$3.22
-1.33 (-29.19%)
54.1% undervalued intrinsic discount
US$7.00
Fair Value
Price US$3.22
AnalystConsensusTarget US$7.00
537578 US$1.97
Talos US$8.38
Fair ValueUS$7.00
Share Pricen/a
Seeking Alpha • Aug 10
Recursion Pharmaceuticals, Inc. Stock Price
- 5 Narratives written by author
- 7 Comments on narratives written by author
- 231 Fair Values set on narratives written by author
RXRX Community Narratives
AN
Fair Value
·Fair Value US$7 54.1% undervalued intrinsic discount
Advanced AI And ML Will Transform Biotech Drug Discovery
0users have liked this narrative
6users have commented on this narrative
137users have followed this narrative
53
Fair Value
·Fair Value US$1.97 63.2% overvalued intrinsic discount
Recursion Pharmaceuticals! WTH is going on?
2users have liked this narrative
0users have commented on this narrative
17users have followed this narrative
TA
Fair Value
·Fair Value US$8.38 61.6% undervalued intrinsic discount
Moving from "Science Fiction" to "Science Fact" – A Bullish Valuation Case
3users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
Recursion Pharmaceuticals
63.2% overvalued intrinsic discount
Recursion Pharmaceuticals! WTH is going on?
View narrative53
Updated 3 May
Recursion Pharmaceuticals
61.6% undervalued intrinsic discount
Moving from "Science Fiction" to "Science Fact" – A Bullish Valuation Case
View narrativeTA
Updated 25 Feb
Recursion Pharmaceuticals
19.6% undervalued intrinsic discount
High R&D Burn And Regulatory Hurdles Will Cripple Future Value
View narrativeAN
Updated 10 Jul
Recursion Pharmaceuticals
67.9% undervalued intrinsic discount
OS 20 Will Accelerate AI Drug Discovery And Clinical Milestones
View narrativeAN
Updated 26 Jun
Recursion Pharmaceuticals
54.1% undervalued intrinsic discount
Advanced AI And ML Will Transform Biotech Drug Discovery
View narrativeAN
Updated 20 Feb
Trending Discussion
No trending discussion available.
Recently Updated Narratives
53
Recursion Pharmaceuticals! WTH is going on?
Fair Value: US$1.97 63.2% overvalued intrinsic discount
17 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
4 likesusers have liked this narrative
TA
Moving from "Science Fiction" to "Science Fact": Recursion’s Q4 Validates a Hyper-Growth Inflection Point
Fair Value: US$8.38 61.6% undervalued intrinsic discount
4 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
RXRX: Fair Value View Balances Index Inclusion Catalyst And Execution Risks
Fair Value: US$4 19.6% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Recursion Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
- -0.97
- -715.69%
- -945.90%
- 1.6%
About RXRX
- Founded
- 2013
- Employees
- 600
- CEO
- WebsiteView website
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
